An interesting situation could develop if one trial was successful. For instance let's say the Eylea-Opt302 combination wasn't superior to Eyelea alone but the Lucentus-OPT302 was superior to Lecentus alone. Are the trials similar enough to compare outcomes if it looked like the Lucentus combo had superior gains to Eyelea? Novartis would likely still be interested in that case? Maybe not as good as success in both trials but potentially a good second best.
An interesting situation could develop if one trial was...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
80.0¢ |
Change
-0.035(4.19%) |
Mkt cap ! $984.8M | |||
| Open | High | Low | Value | Volume |
| 82.0¢ | 82.8¢ | 80.0¢ | $2.636M | 3.214M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 35676 | 80.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 82.0¢ | 73544 | 3 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |